Category Press Releases

Cytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)

Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies for cardiovascular and neuromuscular diseases, announced today that it has…

Read MoreCytokinetics Issues Inducement Grants Under Nasdaq Rule 5635(c)(4)

FDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused on delivering innovative therapies for patients with serious diseases, today…

Read MoreFDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.

Sarepta’s ELEVIDYS Gene Therapy Approved in Japan for Duchenne Muscular Dystrophy

Sarepta’s ELEVIDYS Gene Therapy Gains Landmark Approval in Japan for Duchenne Muscular Dystrophy Sarepta Therapeutics, a biotechnology leader in precision genetic medicine for rare diseases, has announced a significant regulatory milestone: the Japanese Ministry of Health, Labour and Welfare (MHLW)…

Read MoreSarepta’s ELEVIDYS Gene Therapy Approved in Japan for Duchenne Muscular Dystrophy

WuXi Biologics Ireland Advances Sustainability Through Strategic Innovation

WuXi Biologics Ireland: Pioneering Sustainable Biomanufacturing Through Purpose-Driven Innovation In an era where sustainability has become a defining metric of corporate integrity and resilience, WuXi Biologics Ireland stands out as a biopharmaceutical leader integrating environmental, social, and governance (ESG) values…

Read MoreWuXi Biologics Ireland Advances Sustainability Through Strategic Innovation